Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Steven Deitelzweig, Manuela Di Fusco, Amiee Kang, Mirko Savone, Ruth Mokgokong, Allison Keshishian, Cynthia Gutierrez & Joseph C. Cappelleri. (2021) Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Current Medical Research and Opinion 37:6, pages 891-902.
Read now
Read now
Kavitha Vimalesvaran, Seth J Dockrill & Diana A Gorog. (2018) Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. Vascular Health and Risk Management 14, pages 13-21.
Read now
Read now
Xiao Xiang, Yaying Cao, Kexin Sun, Jing Song, Yaohua Tian, Qiongzhou Yin, Juan Juan & Yonghua Hu. (2018) Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China. Current Medical Research and Opinion 34:2, pages 255-261.
Read now
Read now
Leon A. Simons, Michael Ortiz, Ben Freedman, Benjamin J. Waterhouse & David Colquhoun. (2017) Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience. Current Medical Research and Opinion 33:7, pages 1337-1341.
Read now
Read now
Articles from other publishers (20)
Hizir Ozdemir, Dimitrios Sagris, Gregory Y. H. Lip & Azmil H. Abdul-Rahim. (2023) Stroke in Atrial Fibrillation and Other Atrial Dysrhythmias. Current Cardiology Reports 25:5, pages 357-369.
Crossref
Crossref
Luxiang ShangYujiao ZhangYang ZhaoBaopeng TangYinglong Hou. (2022) Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement. BioScience Trends 16:5, pages 317-329.
Crossref
Crossref
Adane Teshome Kefale, Woldesellassie M. Bezabhe & Gregory M. Peterson. (2022) Oral Anticoagulant Discontinuation and Its Predictors in Patients with Atrial Fibrillation. Journal of Clinical Medicine 11:20, pages 6022.
Crossref
Crossref
Christina Christersson, Claes Held, Angelo Modica, Johan Westerbergh & Gorav Batra. (2022) Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation—A SWEDEHEART study. PLOS ONE 17:1, pages e0262580.
Crossref
Crossref
M. Sabaté, X. Vidal, E. Ballarin, M. Rottenkolber, S. Schmiedl, B. Grave, C. Huerta, E. Martin-Merino, D. Montero, L. M. Leon-Muñoz, C. Gasse, N. Moore, C. Droz, R. Lassalle, M. Aakjær, M. Andersen, M. L. De Bruin, P. Souverein, O. H. Klungel, H. Gardarsdottir & L. Ibáñez. (2021) Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015). Frontiers in Pharmacology 12.
Crossref
Crossref
Sireen Abdul Rahim Shilbayeh & Alnada Abdalla Ibrahim. (2020) The anti-clot treatment scale (ACTS): validation of the translated Arabic version among patients undergoing warfarin therapy in Saudi Arabia. Health and Quality of Life Outcomes 18:1.
Crossref
Crossref
Iniya Rathinam, Shailendra Anoopkumar-Dukie, Tony Badrick, Trudy Teasdale & Nijole Bernaitis. (2020) Anticoagulant Initiation During Hospital Admissions for Atrial Fibrillation in South-East Queensland, Australia. Heart, Lung and Circulation 29:9, pages e222-e230.
Crossref
Crossref
Aya F. OzakiAustin S. ChoiQuan T. LeDennis T. KoJanet K. HanSandy S. ParkCynthia A. Jackevicius. (2020) Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes 13:3.
Crossref
Crossref
Miney Paquette, Lionel Riou França, Christine Teutsch, Hans-Christoph Diener, Shihai Lu, Sergio J. Dubner, Chang Sheng Ma, Kenneth J. Rothman, Kristina Zint, Jonathan L. Halperin, Brian Olshansky, Menno V. Huisman, Gregory Y.H. Lip & Robby Nieuwlaat. (2020) Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. The American Journal of Cardiology 125:3, pages 383-391.
Crossref
Crossref
Carlos Martinez, Christopher Wallenhorst, Stephan Rietbrock & Ben Freedman. (2020) Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study. Journal of the American Heart Association 9:2.
Crossref
Crossref
Gilda Denise Zielinski, Nienke van Rein, Martina Teichert, Frederikus A. Klok, Frits R. Rosendaal, Felix J.M. van der Meer, Menno V. Huisman, Suzanne C. Cannegieter & Willem M. Lijfering. (2020) Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Research and Practice in Thrombosis and Haemostasis 4:1, pages 141-153.
Crossref
Crossref
Nicole Lowres, Katrina Giskes, Charlotte Hespe & Ben Freedman. (2019) Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. Korean Circulation Journal 49:10, pages 883.
Crossref
Crossref
Chi-Jen Weng, Cheng-Hung Li, Ying-Chieh Liao, Che-Chen Lin, Jiunn-Cherng Lin, Shih-Lin Chang, Chu-Pin Lo, Kuo-Ching Huang, Jin-Long Huang, Ching-Heng Lin, Yu-Cheng Hsieh & Tsu-Juey Wu. (2018) Rhythm control better prevents stroke and mortality than rate control strategies in patients with atrial fibrillation - A nationwide cohort study. International Journal of Cardiology 270, pages 154-159.
Crossref
Crossref
George Ntaios, Dimitrios Sagris, Fotios Gioulekas, Petros Galanis, Christianna Pardali, Anastasia Vemmou, Eleni Koroboki, Vasileios Papavasileiou, Sofia Vassilopoulou, Efstathios Manios, Konstantinos Makaritsis, Konstantinos Spengos, Dimos-Dimitrios Mitsikostas, Haralambos Milionis & Konstantinos Vemmos. (2018) 20-year trends of characteristics and outcomes of stroke patients with atrial fibrillation. International Journal of Stroke 13:7, pages 707-716.
Crossref
Crossref
Lixiu Wang, Yayan Bi, Muxin Yu, Tao Li, Dongxia Tong, Xiaoyan Yang, Cong Zhang, Li Guo, Chunxu Wang, Yan Kou, Zengxiang Dong, Valerie A. Novakovic, Ye Tian, Junjie Kou, Masood A. Shammas & Jialan Shi. (2018) Phosphatidylserine-exposing blood cells and microparticles induce procoagulant activity in non-valvular atrial fibrillation. International Journal of Cardiology 258, pages 138-143.
Crossref
Crossref
Géric Maura, Cécile Billionnet, François Alla, Joshua J. Gagne & Antoine Pariente. (2018) Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:1, pages 6-18.
Crossref
Crossref
Jared W Magnani, Courtney L Schlusser, Everlyne Kimani, Bruce L Rollman, Michael K Paasche-Orlow & Timothy W Bickmore. (2017) The Atrial Fibrillation Health Literacy Information Technology System: Pilot Assessment. JMIR Cardio 1:2, pages e7.
Crossref
Crossref
Tanja Mueller, Samantha Alvarez-Madrazo, Chris Robertson & Marion Bennie. (2017) Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. Pharmacoepidemiology and Drug Safety 26:11, pages 1378-1386.
Crossref
Crossref
Sujan T. Reddy, TC Cossey, Sean I. Savitz & James C. Grotta. (2017) Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal. Current Neurology and Neuroscience Reports 17:9.
Crossref
Crossref
Nyo Nyo Tun, Ganesan Arunagirinathan, Sunil K Munshi & Joseph M Pappachan. (2017) Diabetes mellitus and stroke: A clinical update. World Journal of Diabetes 8:6, pages 235.
Crossref
Crossref